Into pharma's roaring twenties

“I drained the last of my cocktail, gazing up at the ceiling. It was one of those moments that curls the hairs on your neck. At once, the grand scale of this labyrinth of cathedrals became clear, the desert wind blowing through the clever hieroglyphics carved into every available surface. I turned my head back down to ground level just in time to see the man draw back his fist in anger, and then.And then.With a piercing shriek, he lunged straight at my jaw –”Do you ever wake from a dream, marvelling at the inventiveness and detail of your subconscious mind? That disorienting moment where you lie blinking in darkness, for a second believing it really did happen. Suddenly you admire your own creative abilities in conjure up such a rich and immersive world.It felt so real.It ’s time to summon that subconscious creativity more readily. In the 2020s, such storytelling skills will be vital in finding and communicating a purpose. This skill will separate the winners from the losers. The 2010s: scaling incredible scienceThis past week, I asked twenty pharma and patient friends what they felt was, personally, their biggest moment of the 2010s – and their likely biggest of the next decade.For the decade just passed, the undoubted top choice was the ability to personalise medicine, with nearly two-thirds of respondents citing gene editing as the most impactful development.Simon Davies (Exec Director, Teen Cancer America) shared the moving story of Emil...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

CONCLUSIONS: For peripheral lung cancer, the measurement on CT and routine MRI sequences can potentially replace each other after comprehensive consideration of examination purposes, but for central lung cancer, alternative use of CT and MRI in evaluating treatment responses for lung cancer should needs extra attention. The diameter measurement of lung cancer on DWI is consistent with that on T1WI and T2WI, suggesting that DWI can provide functional and morphological information. PMID: 32083610 [PubMed - as supplied by publisher]
Source: Journal of X-Ray Science and Technology - Category: Radiology Tags: J Xray Sci Technol Source Type: research
Authors: Visochek L, Atias D, Spektor I, Castiel A, Golan T, Cohen-Armon M Abstract [This corrects the article DOI: 10.18632/oncotarget.27268.]. PMID: 32082490 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Lopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A, Zammataro L, Manzano A, Manara P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Raspagliesi F, Angioli R, Buza N, Hui P, Bond HM, Santin AD Abstract Background: Uterine and ovarian carcinosarcomas (CS) are rare cancers with poor prognosis. Sacituzumab-govitecan (SG) is a new class of antibody-drug-conjugate (ADC) targeting the human-trophoblast-cell-surface marker (Trop-2) conjugated with the active metabolite of irinotecan (SN-38). We evaluated the efficacy of SG against biologically ag...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusions: Niche mutations exhibited an increased risk of death when compared with EGFR mutations and a similar risk of death when compared with KRAS mutations. PMID: 32082488 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In this study, we evaluated the effect of FDA-approved kinase inhibitors on GC. Through a combination of cell growth, migration and invasion assays, we identified dasatinib as an efficient inhibitor of GC proliferation. Mass-spectrometry-based selectivity profiling and subsequent knockdown experiments identified members of the SRC family of kinases including SRC, FRK, LYN and YES, as well as other kinases such as DDR1, ABL2, SIK2, RIPK2, EPHA2, and EPHB2 as dasatinib targets. The expression levels of the identified kinases were investigated on RNA and protein level in 200 classified tumor samples from patients, who had und...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Jabalee J, Towle R, Lawson J, Dickman C, Garnis C Abstract Neutral sphingomyelinase 2 (nSMase2), the product of the sphingomyelin phosphodiesterase 3 (SMPD3) gene, catalyzes the hydrolysis of sphingomyelin to ceramide. Ceramide acts on various signaling pathways to influence cell proliferation, survival, and stress response. Altered levels of sphingolipids and ceramides have been reported in various cancer types, including oral squamous cell carcinoma (OSCC). OSCC patients exhibit a poor 5-year survival rate of 50%, a figure that has remained stagnant for decades. To overcome this requires a better underst...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Charan M, Dravid P, Cam M, Setty B, Roberts RD, Houghton PJ, Cam H Abstract The pre-metastatic niche (PMN) represents an abnormal microenvironment devoid of cancer cells, but favoring tumor growth. Little is known about the mechanisms that generate the PMN or their effects on host cells within metastasis-prone organs. Here, we investigated by using spontaneous metastatic models whether lung epithelial cells are essential for primary tumor induced neutrophil recruitment in lung and subsequently initiating PMN formation in osteosarcoma. We found that serum levels of ANGPTL2 in osteosarcoma patients are signi...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Merrigan SL, Park B, Ali Z, Jensen LD, Corson TW, Kennedy BN Abstract Aberrant ocular angiogenesis can underpin vision loss in leading causes of blindness, including neovascular age-related macular degeneration and proliferative diabetic retinopathy. Current pharmacological interventions require repeated invasive administrations, may lack efficacy and are associated with poor patient compliance and tachyphylaxis. Vitamin D has de novo anti-angiogenic properties. Here, our aim was to validate the ocular anti-angiogenic activity of biologically active vitamin D, calcitriol, and selected vitamin D analogue, 2...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Smith AM, Zhang CRC, Cristino AS, Grady JP, Fink JL, Moore AS Abstract [This corrects the article DOI: 10.18632/oncotarget.27206.]. PMID: 32076493 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Correction: Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation. Oncotarget. 2020 Jan 21;11(3):304 Authors: Yan Y, Hein AL, Etekpo A, Burchett KM, Lin C, Enke CA, Batra SK, Cowan KH, Ouellette MM Abstract [This corrects the article DOI: 10.18632/oncotarget.2500.]. PMID: 32076492 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Accidents | Alzheimer's | American Health | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Child Development | Children | Clinical Trials | Diabetes | Diabetes Type 2 | Disability | Electronic Health Records (EHR) | Endocrinology | Esophagus Cancer | Gene Therapy | Genetics | Hives | Hospitals | Infectious Diseases | Laryngeal Cancer | Legislation | Leukemia | Medical Ethics | Men | Merck | Partnerships | Pharmaceuticals | Politics | Rare Diseases | Science | Stem Cell Therapy | Stem Cells | Superbugs | Toxicology | Vaccines | Vitamins